Wolters Kluwer Pharma Solutions, Inc., a US-based provider of market data and competitive intelligence to the pharmaceutical and biotech industries, has introduced a new version of its Adis R&D Insight global pipeline database. Available immediately, the enhanced product seeks to quantify probability of approval and revenue potential for thousands of drugs in development. According to the company, the new Adis R&D Insight is the first research tool to become available that combines quantitative forecasting capabilities with a comprehensive collection of research on pipeline drugs.
Adis R&D Insight is projected to utilise the intelligent forecasting of inThought, the company’s pharmaceutical research service, to assign approvability ratings and generate revenue forecasts. Every active-development drug in the database is assigned an inThought Approvability Index (IAI), which assesses the progress of a drug candidate through clinical development. An evidence-based score is assigned for specific line items relating to safety, efficacy, trial design and other factors in each phase of clinical development. InThought analysts continually update these scores based on clinical trial announcements, results, regulatory activity and other factors.
Complementing the IAI are detailed revenue models, addressing the market potential of approved drugs as well as developmental agents. Employing a proprietary model, inThought applies a consistent set of criteria across each assessment. Revenue models forecast seven years into the future and provide three years of historical data, and are developed separately for the US, Europe and Japan.
Wolters Kluwer Pharma Solutions developed the product in a bid to provide unfettered access to the rationale behind its analysis. It is expected that the tool will allow the customer to drill down into the source data to reveal events in the marketplace that influenced the analysis. For example, when an IAI is upgraded, a customer can link to abstracts associated with the event that led to the change.
Adis R&D Insight is intended for pharma teams responsible for competitive intelligence, business development, and partnership and licensing research — all of whom are tasked with developing their own revenue projections, market forecasts, and competitive intelligence research. Now these groups have an alternative resource to which they can compare their analysis.
Search for more such pharma related information in K-Store
Discuss this NEWS
